Program
Abiraterone Acetate
Also written as “Abiraterone acetate”, “Abiraterone” and “abiraterone acetate”.
Its studies are mostly in Prostatic Neoplasms · Neoplasm Metastasis · Breast Neoplasms · Bulbo-Spinal Atrophy, X-Linked · Prostatic Neoplasms, Castration-Resistant, led by 8 companies.
Drug pageAbiraterone Acetate: every studyMany companies study it; this page follows only the 53 they lead. All 127 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 414 open or running | phase 4since Mar 27, 2015 | May 11, 2007 | none ahead |
| Jiangsu HengRui Medicineits history only | 32 open or running | phase 2since Apr 25, 2021 | Apr 25, 2021 | Dec 2026phase 2 · NCT06568094 |
| Sun Pharmaceutical Industriesits history only | 31 open or running | phase 2since Mar 25, 2016 | Mar 25, 2016 | Dec 31, 2027phase 2 · NCT05422911 |
| Sanofiits history only | 20 open or running | phase 4since Jun 26, 2015 | Jan 4, 2012 | none ahead |
| Boryung Pharmaceuticalits history only | 10 open or running | phase 1since May 12, 2021 | May 12, 2021 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 3since Aug 11, 2019 | Aug 11, 2019 | none ahead |
| Sumitomo Pharmaits history only | 10 open or running | phase 1since Dec 7, 2020 | Dec 7, 2020 | none ahead |
| Zentiva, k.s.its history only | 10 open or running | phase 1since Mar 2, 2020 | Mar 2, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 26 studies since May 11, 2007.
- Sep 25, 2012Phase 3 study in Prostatic NeoplasmsNCT01695135 · 214 enrolled · China
- Oct 22, 20122 phase 1 studiesNCT01798628, NCT01715259
- Oct 24, 2012Phase 3 study in Prostatic NeoplasmsNCT01715285 · 1,209 enrolled · Argentina, Australia, Belgium and more
- Dec 20, 2012Phase 2 study in Prostatic NeoplasmsNCT01756638 · 48 enrolled · Japan
- Jan 30, 2013Phase 2 study in Prostatic NeoplasmsNCT01795703 · 47 enrolled · Japan
- Jun 5, 2013Phase 1 study in Healthy VolunteersNCT01873001 · 16 enrolled · Belgium
- Oct 31, 2013Phase 1 study in Prostatic NeoplasmsNCT02001571 · 24 enrolled · United States
- Apr 21, 2014Phase 1 study in Prostatic NeoplasmsNCT02123758 · 57 enrolled · United States, Canada, Netherlands and more
- Aug 13, 2014Phase 2 study in Prostatic NeoplasmsNCT02217566 · 46 enrolled · Brazil
- Aug 29, 2014Phase 1 study in HealthyNCT02230046 · 102 enrolled · United States
- Mar 27, 2015Phase 4 study in Metastatic Castration-Resistant Prostate CancerNCT02405858 · 51 enrolled · Japan
- Nov 19, 2018Phase 3 study in Prostatic Neoplasms, Castration-ResistantNCT03748641 · 765 enrolled · United States, Argentina, Australia and more
- Jul 31, 2020Phase 3 study in Prostatic NeoplasmsNCT04497844 · 696 enrolled · United States, Argentina, Australia and more
- Oct 5, 2020Phase 1 study in Prostatic NeoplasmsNCT04577833 · 136 enrolled · United States, Belgium, France and more
TargetBeta
“Cytochrome P450 17A1 inhibitor”ChEMBL 37, by rule
Studies
All 41 Johnson & Johnson leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04577833Prostatic Neoplasms · United States, Belgium, France and more | 1 | Active, not recruiting | Oct 15, 2021 | 136 |
| NCT04497844Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 7, 2025 | 696 |
| NCT03748641Prostatic Neoplasms, Castration-Resistant · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 8, 2021 | 765 |
| NCT02405858Metastatic Castration-Resistant Prostate Cancer · Japan | 4 | Completed | Dec 31, 2017 | 51 |
| NCT02230046Healthy · United States | 1 | Completed | Nov 2014 | 102 |
| NCT02217566Prostatic Neoplasms · Brazil | 2 | Completed | Oct 26, 2018 | 46 |
| NCT02123758Prostatic Neoplasms · United States, Canada, Netherlands and more | 1 | Active, not recruiting | Jun 27, 2016 | 57 |
| NCT02001571Prostatic Neoplasms · United States | 1 | Completed | Apr 2010 | 24 |
| NCT01873001Healthy Volunteers · Belgium | 1 | Completed | Jul 2013 | 16 |
| NCT01795703Prostatic Neoplasms · Japan | 2 | Completed | Oct 2014 | 47 |
| NCT01756638Prostatic Neoplasms · Japan | 2 | Completed | Oct 17, 2014 | 48 |
| NCT01715285Prostatic Neoplasms · Argentina, Australia, Belgium and more | 3 | Completed | Oct 31, 2016 | 1,209 |
| NCT01715259Renal Insufficiency · United States | 1 | Completed | Jan 2010 | 16 |
| NCT01798628Healthy Volunteers | 1 | Completed | Oct 2009 | 36 |
| NCT01695135Prostatic Neoplasms · China | 3 | Completed | Jun 20, 2014 | 214 |
| NCT01685983Prostatic Neoplasms · Korea, Republic of, Taiwan | 2 | Completed | Jan 24, 2013 | 82 |
| NCT01678573Healthy · China | 1 | Completed | Sep 2012 | 15 |
| NCT01664728Prostatic Neoplasms · United Kingdom | 1 | Completed | Feb 2009 | 54 |
| NCT01640093Healthy Participants · United States | 1 | Completed | Jul 2012 | 32 |
| NCT01591122Prostatic Neoplasms · China, Malaysia, Russian Federation and more | 3 | Completed | Dec 31, 2016 | 313 |
| NCT01655147Healthy · Belgium | 1 | Completed | Mar 2012 | 19 |
| NCT01517802Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Apr 22, 2021 | 32 |
| NCT01575587Pharmacology · United States | 1 | Completed | May 2012 | 51 |
| NCT01588782Healthy Volunteers · Belgium | 1 | Completed | Feb 2012 | 20 |
| NCT01495910Congenital adrenal hyperplasia due to 21 hydroxylase deficiency · United States | 1 | Completed | Feb 2013 | 6 |
| NCT01424930Prostatic Neoplasms · Canada | 2 | Completed | Apr 2013 | 25 |
| NCT01381874Breast Neoplasms · United States, Belgium, France and more | 2 | Completed | Jul 28, 2014 | 297 |
| NCT01362764Healthy Volunteers | 1 | Completed | Jun 2011 | 30 |
| NCT01314118Prostatic Neoplasms · United States | 2 | Completed | Dec 24, 2013 | 131 |
| NCT01186484Prostatic Neoplasms · Japan | 1 | Completed | Oct 2, 2014 | 27 |
| NCT01017939Prostatic Neoplasms · United States, Canada | 1 | Completed | Jun 2010 | 34 |
| NCT00924469Prostatic Neoplasms · United States | 2 | Completed | Feb 2012 | 58 |
| NCT00910754Prostatic Neoplasms · United States, Canada | 1 | Completed | Nov 2009 | 33 |
| NCT00887198Prostatic Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Mar 31, 2014 | 1,088 |
| NCT00638690Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Aug 2010 | 1,195 |
| NCT00600535Prostatic Neoplasms · United States, United Kingdom | 1 | Completed | Mar 2012 | 31 |
| NCT00544440Prostatic Neoplasms · United States | 2 | Completed | Aug 2012 | 57 |
| NCT00485303Prostatic Neoplasms · United States, United Kingdom | 2 | Completed | Oct 2011 | 58 |
| NCT00474383Prostatic Neoplasms · United States, United Kingdom | 2 | Completed | Aug 2011 | 47 |
| NCT00473746Prostatic Neoplasms · United States | 2 | Completed | Dec 2012 | 66 |
| NCT00473512Prostatic Neoplasms · United Kingdom | 2 | Completed | Nov 2008 | 54 |
How it is read
Names in the registry
- “Abiraterone acetate”, 24 entries
- “Abiraterone”, 10 entries
- “Abiraterone Acetate”, 5 entries
- “abiraterone acetate”, 2 entries
- “Abiraterone acetate (Treatment B)”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 43 studies
- Neoplasm Metastasis, 2 studies
- Breast Neoplasms, 2 studies
- Bulbo-Spinal Atrophy, X-Linked, 1 study
- Prostatic Neoplasms, Castration-Resistant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.